Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423567 | 0.90 | MAPK1 (0.37) | MAPK1CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL15423563 | 0.84 | MAPK1 (0.34) | MAPK1CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL20348813 | 0.78 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL19447708 | 0.77 | MAPT (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL7567670 | 0.76 | BTK (0.37) | MAPK1CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL15617943 | 0.75 | MAPK1 (0.36) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL18743086 | 0.75 | MAPK1 (0.36) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL11892811 | 0.75 | MAPK1 (0.36) | MAPK1MEN1KMT2AEPHX2CHRM2 | |
| SCHEMBL15695026 | 0.73 | ALDH1A1 (0.39) | CYP4F2CYP4A11MEN1KMT2A | |
| SCHEMBL20348810 | 0.72 | LMNA (0.39) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | MAPK1 3681/4885CYP4F2 185/4885CYP4A11 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.